• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Current evidence-based medicine for early intervention in diabetes].

作者信息

Sano Hironari, Tajima Naoko

机构信息

Division of Diabetes,Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine.

出版信息

Nihon Rinsho. 2008 Oct;66(10):2027-32.

PMID:18939508
Abstract

The management of diabetes has changed recently with the early intervention, including diet, exercise, various pharmacological agents and education. In this review, we have provided current evidences of early intervention in various treatments. For example, sulfonylureas, metformin, alpha-glucosidase inhibitors, pioglitazone and glinides appear to be some of the drugs of choice to start with early pharmacological treatment when type 2 diabetic patients continue to have hyperglycemia despite diet and exercise. Clinical studies have shown that insulin therapy should be started sooner at an early stage in the natural progression of the diabetes. Moreover, recent data have demonstrated that treatment with early intervention of lifestyle adjustments as well as some pharmacological agents resulted in greater improvement of glycemic control. Further studies are expected to show the best point of intervention during diabetic course in preventing from progression of diabetic stage and diabetic complications.

摘要

相似文献

1
[Current evidence-based medicine for early intervention in diabetes].
Nihon Rinsho. 2008 Oct;66(10):2027-32.
2
Oral antidiabetic agents: current role in type 2 diabetes mellitus.口服抗糖尿病药物:在2型糖尿病中的当前作用
Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005.
3
Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone.
Am J Cardiol. 2001 Sep 1;88(5):556-7. doi: 10.1016/s0002-9149(01)01739-8.
4
[Management of blood glucose--target of the management and its practice].[血糖管理——管理目标及其实践]
Nihon Rinsho. 2006 Nov;64(11):2089-94.
5
[Diabetes and cancer risk: oncologic considerations].[糖尿病与癌症风险:肿瘤学考量]
Orv Hetil. 2011 Jul 17;152(29):1144-55. doi: 10.1556/OH.2011.29158.
6
Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.2型糖尿病患者开始使用胰岛素治疗时,为何应保留胰岛素增敏剂而非促分泌剂。
Diabetes Metab Res Rev. 2008 Jan-Feb;24(1):3-13. doi: 10.1002/dmrr.783.
7
[Management of postprandial hyperglycemia].
Nihon Rinsho. 1997 Nov;55 Suppl:721-6.
8
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.在接受二甲双胍加磺脲类药物治疗但血糖控制不佳的2型糖尿病患者中,甘精胰岛素与加用罗格列酮的比较。
Diabetes Care. 2006 Nov;29(11):2371-7. doi: 10.2337/dc06-0564.
9
Diabetes and cancer: a consensus report.糖尿病与癌症:共识报告。
CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21. doi: 10.3322/caac.20078. Epub 2010 Jun 16.
10
Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.美国成年糖尿病患者的种族、族裔与噻唑烷二酮类药物的使用情况。
Curr Med Res Opin. 2007 Mar;23(3):489-94. doi: 10.1185/030079906X167354.